| 臺大學術典藏 |
2021-05-03T02:20:41Z |
Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group
|
Andr? T.;Vernerey D.;Im S.A.;Bodoky G.;Buzzoni R.;Reingold S.;Rivera F.;Mckendrick J.;Scheithauer W.;Ravit G.;Fountzilas G.;Yong W.P.;Isaacs R.;?Sterlund P.;Jin-Tung Liang;Creemers G.J.;Rakez M.;Van Cutsem E.;Cunningham D.;Tabernero J.;De Gramont A.; Andr? T.; Vernerey D.; Im S.A.; Bodoky G.; Buzzoni R.; Reingold S.; Rivera F.; McKendrick J.; Scheithauer W.; Ravit G.; Fountzilas G.; Yong W.P.; Isaacs R.; ?sterlund P.; JIN-TUNG LIANG; Creemers G.J.; Rakez M.; Van Cutsem E.; Cunningham D.; Tabernero J.; de Gramont A. |
| 臺大學術典藏 |
2020-01-22T07:50:23Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Chiang Y.-C.; CHI-AN CHEN; Cheng W.-F.; Lee S.-P.;Hsu H.-C.;Tai Y.-J.;Chen Y.-L.;Chiang Y.-C.;Chi-An Chen;Cheng W.-F.; Lee S.-P.; Hsu H.-C.; Tai Y.-J.; Chen Y.-L. |
| 臺大學術典藏 |
2020-02-06T05:21:47Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Hsu H.-C.; Tai Y.-J.; Chen Y.-L.; Chiang Y.-C.; Chen C.-A.; WEN-FANG CHENG; Lee S.-P.; Hsu H.-C.; Tai Y.-J.; Chen Y.-L.; Chiang Y.-C.; Chen C.-A.; WEN-FANG CHENG; WEN-FANG CHENG;Chen C.-A.;Chiang Y.-C.;Chen Y.-L.;Tai Y.-J.;Hsu H.-C.;Lee S.-P.; Lee S.-P. |
| 臺大學術典藏 |
2020-02-14T02:49:36Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Lee S.-P.;Hsu H.-C.;Tai Y.-J.;Chen Y.-L.;Chiang Y.-C.;Chen C.-A.;Wen-Fang Cheng; Lee S.-P.; Hsu H.-C.; Tai Y.-J.; Chen Y.-L.; Chiang Y.-C.; Chen C.-A.; WEN-FANG CHENG |
| 臺大學術典藏 |
2020-02-14T08:50:30Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Lee S.-P; Hsu H.-C; Tai Y.-J; Chen Y.-L; YING-CHENG CHIANG; Chen C.-A; Cheng W.-F. |
| 臺大學術典藏 |
2020-05-24T06:00:15Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Lee S.-P.; Hsu H.-C.; Tai Y.-J.; YU-LI CHEN; Chiang Y.-C.; Chen C.-A.; Cheng W.-F. |
| 臺大學術典藏 |
2021-02-04T02:39:51Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Lee S.-P.;Hsu H.-C.;Tai Y.-J.;Yu-Li Chen;Chiang Y.-C.;Chen C.-A.;Cheng W.-F.; Lee S.-P.; Hsu H.-C.; Tai Y.-J.; YU-LI CHEN; Chiang Y.-C.; Chen C.-A.; Cheng W.-F. |
| 臺大學術典藏 |
2021-02-04T06:11:34Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Lee S.-P.; Hsu H.-C.; YI-JOU TAI; Chen Y.-L.; Chiang Y.-C.; Chen C.-A.; Cheng W.-F. |
| 臺大學術典藏 |
2021-02-04T07:44:50Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Lee S.-P.; Hsu H.-C.; Tai Y.-J.; Chen Y.-L.; YING-CHENG CHIANG; Chen C.-A.; Cheng W.-F. |
| 臺大學術典藏 |
2021-09-27T06:18:43Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Lee S.-P.; HENG-CHENG HSU; Tai Y.-J.; Chen Y.-L.; Chiang Y.-C.; Chen C.-A.; Cheng W.-F. |
| 臺大學術典藏 |
2021-03-10T02:34:33Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Lee S.-P.;Heng-Cheng Hsu;Tai Y.-J.;Chen Y.-L.;Chiang Y.-C.;Chen C.-A.;Cheng W.-F.; Lee S.-P.; HENG-CHENG HSU; Tai Y.-J.; Chen Y.-L.; Chiang Y.-C.; Chen C.-A.; Cheng W.-F. |
| 國立臺灣大學 |
2009 |
Bevacizumab for the Treatment of Corneal Neovascularization
|
陳偉勵; 陳彥名; 朱筱桑; 蔡紫筠; 胡芳蓉; CHEN, WEI-LI; CHEN, YAN-MING; CHU, HSIAO-SANG; TSAI, TZU-YUN; HU, FUNG-RONG |
| 臺大學術典藏 |
2020-10-22T07:41:52Z |
Bevacizumab for the treatment of corneal neovascularization
|
Hu F.-R.; Lin Y.-H.; Tsai T.-Y.; Chu H.-S.; Chen Y.-M.; WEI-LI CHEN |
| 臺大學術典藏 |
2022-07-15T08:17:47Z |
Bevacizumab for the treatment of corneal neovascularization
|
Chen W.-L.; Chen Y.-M.; Chu H.-S.; Lin Y.-H.; Tsai T.-Y.; FUNG-RONG HU |
| 臺大學術典藏 |
2020-05-26T09:26:21Z |
Bevacizumab in EGFR-positive NSCLC: time to change first-line treatment?
|
Chih-Hsin Yang; CHIH-HSIN YANG |
| 國立臺灣大學 |
2009 |
Bevacizumab Is Not Toxic to Retinal Ganglion Cells after Repeated Intravitreal Injection
|
鄭成國; 彭百慧; 田履黛; 陳朝峰; 李憶菁; CHENG, CHENG-KUO; PENG, PAI-HUEI; TIEN, LU-TAI; CHEN, CHAU-FONG; LEE, YIH-JING |
| 國立臺灣大學 |
2016 |
Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis
|
Chen, I-Chun; Lin, Ching-Hung; Jan, I-Shiow; Cheng, Ann-Lii; Lu, Yen-Shen; 盧彥伸; 林璟宏; 詹一秀; 陳怡君; 鄭安理; 林季宏 |
| 臺大學術典藏 |
2018-09-10T09:41:56Z |
Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis
|
Chen, I-Chun;Lin, Ching-Hung;Jan, I-Shiow;Cheng, Ann-Lii;Lu, Yen-Shen;林季宏; Chen, I-Chun;Lin, Ching-Hung;Jan, I-Shiow;Cheng, Ann-Lii;Lu, Yen-Shen; Chen, I-Chun;Lin, Ching-Hung;Jan, I-Shiow;Cheng, Ann-Lii;Lu, Yen-Shen; 盧彥伸;林璟宏;詹一秀;陳怡君;鄭安理;林季宏; I-SHIOW JAN; Kao, Jia-Horng; Chen, I-Chun; Lin, Ching-Hung; CHING-HUNG LIN; Lin, Ching-Hung; ANN-LII CHENG; Jan, I-Shiow; Jan, I-Shiow; Cheng, Ann-Lii; Cheng, Ann-Lii; Lu, Yen-Shen; Lu, Yen-Shen; 高嘉宏 |
| 臺大學術典藏 |
2020-05-25T06:51:50Z |
Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis
|
Chen I.-C;Lin C.-H;Jan I.-S;Cheng A.-L;Yen-Shen Lu; Chen I.-C; Lin C.-H; Jan I.-S; Cheng A.-L; YEN-SHEN LU |
| 臺大學術典藏 |
2021-08-16T03:26:39Z |
Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis
|
I-CHUN CHEN; Lin C.-H.; Jan I.-S.; Cheng A.-L.; Lu Y.-S. |
| 臺大學術典藏 |
2021-08-31T06:29:44Z |
Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis
|
Chen I.-C.; Lin C.-H.; Jan I.-S.; ANN-LII CHENG; Lu Y.-S. |
| 臺大學術典藏 |
2021-03-12T00:50:54Z |
Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis
|
Chen I.-C.; Lin C.-H.; I-SHIOW JAN; Cheng A.-L.; Lu Y.-S. |
| 臺北醫學大學 |
2012 |
Bevacizumab plus Docetaxel and Cisplatin for Metastatic Breast Cancer: A Pilot Phase II Study
|
CJ, Tai;CS, Chen;CS, Hung;LJ, Kuo;PL, Wei;JF, Chiou;CH, Hsu;HY, Chiou;CH, Wu |
| 臺大學術典藏 |
2021-03-18T03:23:37Z |
Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy
|
Lu Y.-S.; WEI-WU CHEN; Lin C.-H.; Yeh D.-C.; Tseng L.-M.; Wu P.-F.; Rau K.-M.; Chen B.-B.; Chao T.-C.; Huang S.-M.; Huang C.-S.; Shih T.T.-F.; Cheng A.-L.; Taiwan Breast Cancer Consortium |
| 臺大學術典藏 |
2021-08-31T06:29:51Z |
Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy
|
Lu Y.-S.; Chen T.W.-W.; Lin C.-H.; Yeh D.-C.; Tseng L.-M.; Wu P.-F.; Rau K.-M.; Chen B.-B.; Chao T.-C.; Huang S.-M.; Huang C.-S.; Shih T.T.-F.; ANN-LII CHENG; Taiwan Breast Cancer Consortium |
